Rasmuson T, Grankvist K, Ljungberg B
Department of Oncology, University of Umeå, Sweden.
Cancer. 1993 Aug 15;72(4):1324-8. doi: 10.1002/1097-0142(19930815)72:4<1324::aid-cncr2820720429>3.0.co;2-w.
Increased levels of gamma-enolase (gamma-enolase) have been observed in the sera of patients with renal cell carcinoma. To evaluate the prognostic information of gamma-enolase in this disease, 161 consecutive patients were assessed before initiation of therapy.
gamma-Enolase was analyzed in serum using an immunoradiometric assay. The patients were clinically staged and followed up for a median time of 36 months (range, 5-104 months). Actuarial survival was calculated using the Kaplan-Meier method.
Elevated levels of gamma-enolase was found in 28 of 61 (46%) patients with distant metastases, compared with 8 of 56 (14%) when the tumor was confined to the kidney. A correlation also was observed between gamma-enolase and tumor grade, with poorly differentiated tumors having the highest levels. In 28 patients with distant metastases and elevated gamma-enolase, the survival time was significantly shorter than that of 31 patients with normal gamma-enolase levels (P < 0.001). The median survival time was 5 and 11 months, respectively. Using Cox proportional hazard model, clinical stage, serum gamma-enolase, and tumor grade were identified as independent prognostic factors.
Serum gamma-enolase can be useful as an adjunct in the staging of renal cell carcinoma. It also gives predictive information and might be of value as a marker in adjuvant therapy.
在肾细胞癌患者的血清中已观察到γ-烯醇化酶（γ-enolase）水平升高。为评估γ-烯醇化酶在该疾病中的预后信息，在治疗开始前对161例连续患者进行了评估。
采用免疫放射分析法定量检测血清中的γ-烯醇化酶。对患者进行临床分期，并随访中位时间36个月（范围5 - 104个月）。采用Kaplan-Meier法计算精算生存率。
61例发生远处转移的患者中有28例（46%）γ-烯醇化酶水平升高，而肿瘤局限于肾脏的56例患者中有8例（14%）升高。还观察到γ-烯醇化酶与肿瘤分级之间存在相关性，分化差的肿瘤γ-烯醇化酶水平最高。在28例发生远处转移且γ-烯醇化酶水平升高的患者中，生存时间显著短于31例γ-烯醇化酶水平正常的患者（P < 0.001）。中位生存时间分别为5个月和11个月。使用Cox比例风险模型，临床分期、血清γ-烯醇化酶和肿瘤分级被确定为独立的预后因素。
血清γ-烯醇化酶可作为肾细胞癌分期的辅助手段。它还能提供预测信息，可能作为辅助治疗的标志物具有价值。
